抗菌药物规范化管理对我院美罗培南应用的影响
|
摘要
目的:探讨抗菌药物规范化管理对医院美罗培南应用的影响。方法:以本院2016年8月-2016年12月期间90例抗菌药物应用患者作为对照组,以本院2017年1月-2017年5月期间90例抗菌药物应用患者作为研究组,自2017年1月开始加强特殊抗菌药美罗培南的规范化管理,比较两组用药合理性、有效性与药物副作用的差异。结果:研究组美罗培南平均用药时间(4.81±1.03)d,明显短于对照组(6.96±1.62)d,美罗培南应用率(27.78%)明显低于对照组(50.00%),两组比较具有显著性差异(P<0.05)。研究组用药不合理率16.67%(15/90),明显低于对照组的50.00%(45/90),两组比较具有显著性差异(P<0.05)。研究组治疗总有效率96.67%,明显高于对照组77.78%,两组比较也具有显著性差异(P<0.05),但两组药物副作用发生率比较(2.22%vs4.44%)不具有显著性差异(P>0.05)。结论:抗菌药物规范化管理指导医院美罗培南的临床合理应用,值得临床进一步推广应用。
Objective: To discuss the effect of standardized management of antibiotics on the application of Meropenem in hospitals. Methods: 90 cases of patients administrated antibiotics from August 2016 to December2016 in our hospital were used as control group, 90 cases of patients administrated antibiotics from January 2017 to May 2017 in our hospital were used as study group. The standardized management of the special antibiotics,Meropenem had been strengthened since January 2017. The differences of rationality, effectiveness and adverse drug reaction of the two groups were compared. Results: Average duration(4.81±1.03)d of Meropenem in the study group was significantly shorter than that(6.96±1.62)d of the control group. The application rate of Meropenem(27.78%) in the study group was significantly lower than that in the control group(50.00%),showing statistically significant difference(P<0.05). The irrational rate of the study group was 16.67%(15/90),significantly lower than that of the control group 50.00%(45/90), showing statistically significant difference(P< 0.05). The total effective rate of the study group(96.67%) was significantly higher than that of the control group which was 77.78%, showing statistically significant difference(P<0.05). However, the rate of the adverse drug reaction between the two groups(2.22% vs 4.44%) did not show statistically significant difference(P>0.05). Conclusion: The standardized management of antibiotics to guide the rational application of Meropenem in hospitals is worthy of clinical popularization and application.
Objective: To discuss the effect of standardized management of antibiotics on the application of Meropenem in hospitals. Methods: 90 cases of patients administrated antibiotics from August 2016 to December2016 in our hospital were used as control group, 90 cases of patients administrated antibiotics from January 2017 to May 2017 in our hospital were used as study group. The standardized management of the special antibiotics,Meropenem had been strengthened since January 2017. The differences of rationality, effectiveness and adverse drug reaction of the two groups were compared. Results: Average duration(4.81±1.03)d of Meropenem in the study group was significantly shorter than that(6.96±1.62)d of the control group. The application rate of Meropenem(27.78%) in the study group was significantly lower than that in the control group(50.00%),showing statistically significant difference(P<0.05). The irrational rate of the study group was 16.67%(15/90),significantly lower than that of the control group 50.00%(45/90), showing statistically significant difference(P< 0.05). The total effective rate of the study group(96.67%) was significantly higher than that of the control group which was 77.78%, showing statistically significant difference(P<0.05). However, the rate of the adverse drug reaction between the two groups(2.22% vs 4.44%) did not show statistically significant difference(P>0.05). Conclusion: The standardized management of antibiotics to guide the rational application of Meropenem in hospitals is worthy of clinical popularization and application.
引文
[1]蔡红梅.调查分析某院2014-2015年抗菌药物应用的合理性[J].现代医药卫生,2017,33(3):433-435.
[2]宋攀,黄垂国,李云龙,等.抗菌药物在外科的不合理应用及对策[J].中华医院感染学杂志,2017,27(3):717-720.
[3]Jacob J,Rajendran R U,Priya S H,et al.Enhanced Antibacterial Metabolite Production through the Application of Statistical Methodologies by a Streptomyces Nogalater NIIST A30 Isolated from Western Ghats Forest Soil[J].Plos One,2017,12(4):175-179.
[4]Yan Z,Kang Y,Wen X,et al.Effect of Amino Acids and Glycyl Dipeptides on Micellization of Antibacterial Drug Domiphen Bromide[J].Journal of Surfactants&Detergents,2017,18(2):1-10.
[5]陈新谦,金有豫,汤光.新编药物学.17版[M].北京:人民卫生出版社,2011.
[6]王桂芝,张丽香,郭宪清,等.367例普外科Ⅰ类切口手术围术期抗菌药物预防性应用情况观察[J].中国实用医药,2017,12(6):128-130.
[7]顾红燕,金锐,谢猛,等.药学干预在医院美罗培南不合理使用管理中的作用[J].中国医院药学杂志,2016,36(14):1209-1212.
[8]贾自力,武明芬,崔喜凤,等.临床药师对美罗培南合理应用的干预效果探讨[J].中国医院用药评价与分析,2018,18(6):847-849,852.
[9]WHO.Worldwide Country Situation Analysis:Response to Antimicrobial Resistance[S].2015.
[10]吴健,高家荣,李颖,等.142例美罗培南临床应用分析[J].中国药物评价,2013,30(1):19-21.
[11]Aravamuthan A,Arputhavanan M,Subramaniam K,et al.Assessment of Current PrescribingPractices Using World Health Organization Core Drug Use and Complementary Indicators in Selected Rural Community Pharmacies in Southern India[J].Journal of Pharmaceutical Policy and Practice,2017,10(1):1.
[12]曲晓宇,陶娌娜,董雷,等.吉林大学白求恩第一医院美罗培南临床应用分析[J].中国医院用药评价与分析,2013,13(5):434-438.
[13]Volkow,Nora D,Poznyak,et al.Drug Use Disorders:Impact of a Public Health Rather than a Criminal Justice Approach[J].World Psychiatry,2017,16(2):213-214.
[14]吴玉婷.美罗培南致药物性肝损伤1例[J].中国药物应用与监测,2017,14(1):66-68.
[15]赵永峰,王仙,朱慧娟.改变美罗培南输注方式对恶性血液病伴发热患者临床疗效的研究[J].中国药物应用与监测,2017,14(1):6-9.
[16]陈婷,黄晓会,陈霁晖,等.老年患者美罗培南血药浓度监测结果分析及药物动力学研究[J].中国药师,2017,20(3):402-404.
[17]岑艳灵,李亚楠,孔晋亮,等.黄芩苷联合美罗培南对小鼠腹腔铜绿假单胞菌早期生物被膜的体内影响[J].中华医院感染学杂志,2017,27(1):39-42.
[18]张静.浅论大肠埃希菌的耐药性及相关抗菌药物的使用情况[J].当代医药论丛,2017,15(1):95-96.
[2]宋攀,黄垂国,李云龙,等.抗菌药物在外科的不合理应用及对策[J].中华医院感染学杂志,2017,27(3):717-720.
[3]Jacob J,Rajendran R U,Priya S H,et al.Enhanced Antibacterial Metabolite Production through the Application of Statistical Methodologies by a Streptomyces Nogalater NIIST A30 Isolated from Western Ghats Forest Soil[J].Plos One,2017,12(4):175-179.
[4]Yan Z,Kang Y,Wen X,et al.Effect of Amino Acids and Glycyl Dipeptides on Micellization of Antibacterial Drug Domiphen Bromide[J].Journal of Surfactants&Detergents,2017,18(2):1-10.
[5]陈新谦,金有豫,汤光.新编药物学.17版[M].北京:人民卫生出版社,2011.
[6]王桂芝,张丽香,郭宪清,等.367例普外科Ⅰ类切口手术围术期抗菌药物预防性应用情况观察[J].中国实用医药,2017,12(6):128-130.
[7]顾红燕,金锐,谢猛,等.药学干预在医院美罗培南不合理使用管理中的作用[J].中国医院药学杂志,2016,36(14):1209-1212.
[8]贾自力,武明芬,崔喜凤,等.临床药师对美罗培南合理应用的干预效果探讨[J].中国医院用药评价与分析,2018,18(6):847-849,852.
[9]WHO.Worldwide Country Situation Analysis:Response to Antimicrobial Resistance[S].2015.
[10]吴健,高家荣,李颖,等.142例美罗培南临床应用分析[J].中国药物评价,2013,30(1):19-21.
[11]Aravamuthan A,Arputhavanan M,Subramaniam K,et al.Assessment of Current PrescribingPractices Using World Health Organization Core Drug Use and Complementary Indicators in Selected Rural Community Pharmacies in Southern India[J].Journal of Pharmaceutical Policy and Practice,2017,10(1):1.
[12]曲晓宇,陶娌娜,董雷,等.吉林大学白求恩第一医院美罗培南临床应用分析[J].中国医院用药评价与分析,2013,13(5):434-438.
[13]Volkow,Nora D,Poznyak,et al.Drug Use Disorders:Impact of a Public Health Rather than a Criminal Justice Approach[J].World Psychiatry,2017,16(2):213-214.
[14]吴玉婷.美罗培南致药物性肝损伤1例[J].中国药物应用与监测,2017,14(1):66-68.
[15]赵永峰,王仙,朱慧娟.改变美罗培南输注方式对恶性血液病伴发热患者临床疗效的研究[J].中国药物应用与监测,2017,14(1):6-9.
[16]陈婷,黄晓会,陈霁晖,等.老年患者美罗培南血药浓度监测结果分析及药物动力学研究[J].中国药师,2017,20(3):402-404.
[17]岑艳灵,李亚楠,孔晋亮,等.黄芩苷联合美罗培南对小鼠腹腔铜绿假单胞菌早期生物被膜的体内影响[J].中华医院感染学杂志,2017,27(1):39-42.
[18]张静.浅论大肠埃希菌的耐药性及相关抗菌药物的使用情况[J].当代医药论丛,2017,15(1):95-96.